XML 26 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Available-for-sale Securities [Table Text Block]
    March 31, 2016
    Amortized
Cost
  Accrued
Interest
  Gross
Unrealized
Gains
  Gross
Unrealized
Losses
  Estimated
Fair Value
Obligations of the U.S. Government and its agencies   $ 21,666     $ 53     $ 15     $ (6 )   $ 21,728  
Corporate debt securities     20,718       94       23       (3 )     20,832  
Certificates of deposit     21,438       32       26       (8 )     21,488  
                                         
Total investments   $ 63,822     $ 179     $ 64     $ (17 )   $ 64,048  
    December 31, 2015
    Amortized
Cost
  Accrued
Interest
  Gross
Unrealized
Gains
  Gross
Unrealized
Losses
  Estimated
Fair Value
Obligations of the U.S. Government and its agencies   $ 26,557     $ 88     $     $ (99 )   $ 26,546  
Corporate debt securities     21,820       184             (41 )     21,963  
Certificates of deposit     21,884       21       5       (72 )     21,838  
                                         
Total investments   $ 70,261     $ 293     $ 5     $ (212 )   $ 70,347  
Available For Sale Securities Debt Maturities Fair Value [Table Text Block]
    2016   2015
Maturing in one year or less   $ 22,914     $ 22,664  
Maturing after one year through two years     32,806       28,395  
Maturing after two years     8,328       19,288  
                 
Total investments   $ 64,048     $ 70,347  
Schedule of Receivables from Collaborations [Table Text Block]
    March 31, 2016
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $ 2,475     $ 2,734     $ 5,209  
Shionogi & Co. Ltd.     1,685             1,685  
Seqirus UK Limited     336       154       490  
                         
Total receivables   $ 4,496     $ 2,888     $ 7,384  
    December 31, 2015
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $     $ 5,536     $ 5,536  
Shionogi & Co. Ltd.     469             469  
 Seqirus UK Limited     210       28       238  
Total receivables   $ 679     $ 5,564     $ 6,243  
Schedule of Inventory, Current [Table Text Block]
    2016   2015
Work in process   $ 1,949     $ 1,612  
                 
Inventories   $ 1,949     $ 1,612  
Schedule of Revenues from Collaborations [Table Text Block]
    2016   2015
Product sales, net   $     $ 537  
Royalty revenue     1,890       1,518  
Collaborative and other research and development revenues:                
U.S. Department of Health and Human Services     2,324       4,475  
Shionogi & Co., Ltd.     296       296  
Seqirus UK Limited     310        
Total collaborative and other research and development revenues     2,930       4,771  
                 
Total revenues   $ 4,820     $ 6,826